Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Arabinosyl transferases (EmbA, EmbB, and EmbC) are membrane-bound enzymes in *Mycobacterium tuberculosis* that catalyze the polymerization of arabinose residues to form arabinogalactan and lipoarabinomannan, essential components of the mycobacterial cell wall. Ethambutol inhibits these enzymes, disrupting cell wall synthesis and leading to a bacteriostatic effect.
Ethambutol inhibits arabinosyl transferases (EmbA, EmbB, and EmbC), blocking the formation of arabinogalactan and lipoarabinomannan, increasing cell wall permeability, disrupting mycolic acid attachment, and leading to bacteriostasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arabinosyl transferase.